Literature DB >> 20066748

Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China.

Ming Shi1, Ji-An Chen, Xiao-Jun Lin, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Ya-Qi Zhang, Jin-Qing Li.   

Abstract

AIM: To identify prognostic factors from pretreatment variables of the initial transarterial chemoembolization (TACE) procedure in unresectable hepatocellular carcinoma (HCC).
METHODS: One thousand and five hundred and sixty-nine patients with unresectable HCC underwent TACE as initial treatment were retrospectively studied. Pretreatment variables of the initial TACE procedure with a P value less than 0.05 by univariate analysis were subjected to Cox proportional hazards model.
RESULTS: The median overall survival time and 1-, 5-, 10-year survival rates were 10.37 mo, 47%, 10%, and 7%, respectively. A Cox proportional hazard model showed that 8 pretreatment factors of regional lymph nodes metastasis, Child-Pugh class, macrovascular invasion, greatest dimension, alpha-fetoprotein (AFP), Hepatitis virus B, tumor capsule, and nodules were independent prognostic factors. Patients with multimodality therapy have better survival than those with TACE treatment only.
CONCLUSION: Tumor status, hepatic function reserve, AFP, and hepatitis virus B status were independent prognostic factors for unresectable HCC. Distant metastasis might not be a contraindication to TACE. Multimodality therapy might improve survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066748      PMCID: PMC2806567          DOI: 10.3748/wjg.v16.i2.264

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  L Lladó; J Virgili; J Figueras; C Valls; J Dominguez; A Rafecas; J Torras; J Fabregat; J Guardiola; E Jaurrieta
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

3.  Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.

Authors:  K Ueno; N Miyazono; H Inoue; H Nishida; I Kanetsuki; M Nakajo
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

6.  Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study.

Authors:  E Caturelli; D A Siena; S Fusilli; M R Villani; G Schiavone; M Nardella; S Balzano; F Florio
Journal:  Radiology       Date:  2000-04       Impact factor: 11.105

7.  Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management.

Authors:  Y Hatanaka; Y Yamashita; M Takahashi; Y Koga; R Saito; K Nakashima; J Urata; M Miyao
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

8.  Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization.

Authors:  Masafumi Ikeda; Shuichi Okada; Seiichiro Yamamoto; Tosiya Sato; Hideki Ueno; Takuji Okusaka; Hitoshi Kuriyama; Kenichi Takayasu; Hiroyoshi Furukawa; Ryoko Iwata
Journal:  Jpn J Clin Oncol       Date:  2002-11       Impact factor: 3.019

9.  Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials.

Authors:  Franck Bonnetain; Xavier Paoletti; Sandra Collette; Michel Doffoel; Olivia Bouché; Jean Luc Raoul; Philippe Rougier; Fadil Masskouri; Jean Claude Barbare; Laurent Bedenne
Journal:  Qual Life Res       Date:  2008-07-10       Impact factor: 4.147

10.  A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization.

Authors:  Igor Dvorchik; Brian I Carr
Journal:  Cancer Detect Prev       Date:  2007-04-09
View more
  22 in total

1.  Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification.

Authors:  Zhi-Jie Niu; Yi-Long Ma; Ping Kang; Sheng-Qiu Ou; Zhi-Bin Meng; Zhi-Kun Li; Feng Qi; Chang Zhao
Journal:  Med Oncol       Date:  2011-12-27       Impact factor: 3.064

2.  The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization.

Authors:  Tong-Chun Xue; Qing-An Jia; Ning-Ling Ge; Bo-Heng Zhang; Yan-Hong Wang; Zheng-Gang Ren; Sheng-Long Ye
Journal:  Tumour Biol       Date:  2015-03-04

Review 3.  Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma.

Authors:  Shashi B Paul; Hanish Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-05-24

4.  Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study.

Authors:  Qiang-Sheng Dai; Hong-Lin Gu; Sheng Ye; Yao-Jun Zhang; Xiao-Jun Lin; Wan Yee Lau; Zhen-Wei Peng; Min-Shan Chen
Journal:  Mol Clin Oncol       Date:  2014-08-18

5.  Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver.

Authors:  Qi-Bo Wang; Bo-Kang Cui; Jian-Ming Weng; Qiu-Liang Wu; Ji-Liang Qiu; Xiao-Jun Lin
Journal:  J Gastrointest Surg       Date:  2012-07-06       Impact factor: 3.452

6.  miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma.

Authors:  Ting-Yi Sun; Hong-Jian Xie; Zhen Li; Ling-Fei Kong; Xiang-Nan Gou; Du-Juan Li; Yu-Jie Shi; Yan-Zhi Ding
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

7.  Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma.

Authors:  Heung Cheol Kim; Ki Tae Suk; Dong Joon Kim; Jai Hoon Yoon; Yeon Soo Kim; Gwang Ho Baik; Jin Bong Kim; Chang Hoon Kim; Hotaik Sung; Jong Young Choi; Kwang Hyub Han; Seung Ha Park
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

8.  Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital.

Authors:  Youhui Wang; Yanping Shen
Journal:  Int J Clin Exp Med       Date:  2013-05-22

9.  Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Guosheng Yuan; Yuchen Zhou; Hao Zhang; Junjie Wang; Nianhuan Yang; Yabing Guo; Dinghua Yang; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.

Authors:  Wenzhe Fan; Yingqiang Zhang; Yu Wang; Xuehua Yao; Jianyong Yang; Jiaping Li
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.